Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901Administered Via Intravenous Infusion as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Selected Advanced Solid Tumors With Cohort Expansions at the Recommended Phase 2 Dose

Next Previous
Search
Trial Profile

A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901Administered Via Intravenous Infusion as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Selected Advanced Solid Tumors With Cohort Expansions at the Recommended Phase 2 Dose

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Q 901 (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Endometrial cancer; HER2 negative breast cancer; Male breast cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Qurient Co

    • Most Recent Events

    • 04 Jun 2024 Interim results of phase I study (as of data cutoff 12 Jan 2024, n=17) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 21 May 2024 According to an Qurient Co Ltd media release, the company entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute (NCI) for Phase 1/2 Clinical Study of Q901.
    • 24 Oct 2023 Trial design presented at the 48th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top